期刊
CLINICAL PHARMACOLOGY & THERAPEUTICS
卷 86, 期 2, 页码 216-220出版社
WILEY
DOI: 10.1038/clpt.2009.117
关键词
-
资金
- Department of Veterans Affairs, Veterans Health Administration
- Office of Research and Development, Biomedical Laboratory Research and Development
- National Institutes of Health [RO1s HL-063915, HL-73986]
- American Heart Association Heartland
- University of Iowa
Systolic heart failure is a feed-forward phenomenon with devastating consequences. Impaired cardiac function is the initiating event, but central nervous system mechanisms activated by persistent altered neural and humoral signals from the periphery play an important sustaining role. Animals with experimentally induced heart failure have neurochemical abnormalities in the brain that, when manipulated, profoundly affect sympathetic drive, volume regulation, and cardiac remodeling-critical determinants of outcome. This brief review explores recent studies that provide a strong rationale for the development of pharmaceutical agents that target central nervous system abnormalities in heart failure.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据